Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Norvir 400% Price Hike Gets Appeals Court OK; Abbott Can Thank AT&T

Executive Summary

Drug firms should have fewer antitrust worries when making formulation and pricing changes for their products based on a recent appeals court decision

You may also be interested in...

Grocery stores sue Abbott over Norvir pricing

Safeway, Walgreens, Kroger, New Albertson's and American Sales Company file an antitrust complaint against Abbott Oct. 26 claiming that its 400 percent Norvir price hike in 2003 restricted competition in the market for protease inhibitor boosters. Abbott increased the wholesale price of Norvir from $205.74 to $1,028.71 but did not increase the price of its Kaletra, which incorporates Norvir. The price hike drastically increased the price of competing regimens using Norvir to boost PIs, the complaint says, forcing plaintiffs to pay higher prices. The Prescription Access Litigation filed a similar class action antitrust suit against Abbott in 2004...

CooperSurgical Lands US FDA Warning Letter Over ParaGuard TV Spot

The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.

Supreme Court May Find Patent Board Judges Unconstitutionally Appointed But Favor Narrow Fix

During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts